Connect Biopharma Completes Enrollment for Phase 2 Asthma Study; Topline Data Expected Early September
CNTB has more than doubled off its 52-week low of $0.91.
Summary
Connect Biopharma announced the completion of enrollment for its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart. This milestone confirms progress in the company's pipeline, following recent positive Phase 3 results for rademikibart in atopic dermatitis and a significant private placement. The company expects to report topline data from this asthma study in early September 2026, which will be a key catalyst for the stock. They also anticipate completing enrollment for a related COPD study this month and plan to meet with the FDA for a Phase 3 program later this year. The company maintains a strong balance sheet with cash runway into the second half of 2027.
At the time of this announcement, CNTB was trading at $2.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.3M. The 52-week trading range was $0.91 to $3.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.